Divamics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Divamics - overview
Established
2021
Location
Suzhou, Jiangsu, China
Primary Industry
Pharmaceuticals
About
Established in 2021 and based in Suzhou, China, Divamics operates as a biopharmaceutical company that focuses on providing AI pharmaceutical services. Zheng Zheng, the company's founder and CEO, has a PhD in Chemistry from the University of Florida. In May 2025, the company closed series A funding from new investors YuanBio Venture. In August 2025, Divamics closed a Strategic Investment from new investor Suzhou Angel Investment Guidance Fund.
The company focuses on new drug research and development. The main products are computational chemistry services and new drug research and development pipeline projects based on artificial intelligence drug research and development platforms. Computational chemistry services include target drugability analysis, high-flexibility target modeling, and macromolecular and small molecule drug structure screening. The new drug research and development pipeline includes IMC001, IMC002, IMC008, etc.
Among them, IMC001 is indicated for EpCAM-positive advanced gastric cancer and esophagogastric junction adenocarcinoma. The company generates revenue by providing computational chemistry services and new drug research and development services.
Current Investors
Shileng Investment, Shanghai Fosun Pharmaceutical (Group), Sino-Singapore Suzhou Industrial Park Industrial Investment
Primary Industry
Pharmaceuticals
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceuticals
Website
www.divamicsbio.com
Verticals
Artificial Intelligence
Company Stage
Series A
Total Amount Raised
Subscriber access only
Divamics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.